<scp>C</scp>hina national lung cancer screening guideline with low‐dose computed tomography (2015 version)
Qinghua Zhou(Sichuan University), You‐Lin Qiao(Chinese Academy of Medical Sciences & Peking Union Medical College), Ya‐guang Fan(Tianjin Medical University General Hospital), Yunchao Huang(North China University of Water Resources and Electric Power), Ning Wu(Regeneron (United States)), Guiqi Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xin‐yun Wang(Tianjin Medical University General Hospital), Hong Bu(Sichuan University), Ying Wang(Henan University)
Cited by 89
Related Papers
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Variations in the age‐specific curves of human papillomavirus prevalence in women worldwide
|International Journal of Cancer|2006|417
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415